- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.03. | Procaps Group, S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 05.02. | Procaps Group appoints Jose Vieira as CEO | 2 | Investing.com | ||
| 16.01. | Procaps Group, S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 05.01. | Procaps Group, S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.12.23 | Pharma Company Procaps Beats On Q3 But Lowers FY23 Guidance: Here's Why | 1 | Benzinga.com | ||
| 27.12.23 | Procaps Group reports Q3 results; updates FY23 outlook | 2 | Seeking Alpha | ||
| 26.12.23 | Procaps Group Reports Third Quarter 2023 Results | 225 | Business Wire | MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group, S.A. (NASDAQ: PROC) ("Procaps" or the "Company"), a leading integrated international healthcare and pharmaceutical services company... ► Artikel lesen | |
| 26.12.23 | Procaps Group, S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 22.11.23 | Procaps Group Appoints Jose Antonio Vieira To Succeed Ruben Minski As CEO | 1 | RTTNews | ||
| 22.11.23 | Procaps Group says CEO Minski to step down from the role | 1 | Seeking Alpha | ||
| 22.11.23 | Procaps Group, S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.11.23 | Procaps Gr Earnings Preview | 1 | Benzinga.com | ||
| 16.10.23 | Procaps Group to Participate at CPHI Barcelona 2023 | 293 | Business Wire | Procaps Group (NASDAQ: PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced today that it will participate at the CPHI Barcelona 2023, that will take... ► Artikel lesen | |
| 05.09.23 | Procaps Group Reports Second Quarter 2023 Results | 232 | Business Wire | MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group, S.A. (NASDAQ: PROC) ("Procaps" or the "Company"), a leading integrated international healthcare and pharmaceutical services company... ► Artikel lesen | |
| 06.06.23 | Procaps Group, S.A.: Procaps Group Reports First Quarter 2023 Results | 417 | GlobeNewswire (Europe) | MIAMI and BARRANQUILLA, Colombia, June 05, 2023 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) ("Procaps"), a leading integrated international healthcare and pharmaceutical services company... ► Artikel lesen | |
| 12.05.23 | Procaps Group Reports Fourth Quarter and Full Year 2022 Results | 432 | Business Wire | MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group S.A. (NASDAQ: PROC) ("Procaps"), a leading integrated international healthcare and pharmaceutical services company, today announced... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AURORA CANNABIS | 6,290 | +0,48 % | Investors Shuffle Stock Positions In Aurora Cannabis: Beyond Earnings, Liquidity Looks Appealing | ||
| CANOPY GROWTH | 8,370 | +0,48 % | Spotlight on Canopy Growth: Analyzing the Surge in Options Activity | ||
| TILRAY BRANDS | 1,670 | +0,09 % | Tilray Aktie: Achterbahnfahrt setzt sich fort | Zum Ende einer bewegten Woche notiert die Aktie des Unternehmens Tilray bei 1.62 €, was einer leichten Veränderung von -0.09% im Vergleich zur Vorwoche entspricht. Die Hoffnungen auf Lockerungen der... ► Artikel lesen | |
| TEVA | 12,950 | 0,00 % | Teva feiert 50 Jahre ratiopharm / Jubiläumsveranstaltung von Deutschlands bekanntester Arzneimittelmarke | Ulm (ots) - Gute Preise. Gute Besserung. Dieses Versprechen hält ratiopharm als erstes deutsches Generika Unternehmen seit 1973. 50 Jahre später, 2023, feierte Teva den runden ratiopharm-Geburtstag... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 371,55 | +0,04 % | Vertex Pharmaceuticals: Vertex Announces European Commission Approval for KALYDECO to Treat Infants With Cystic Fibrosis Ages 1 Month and Older | KALYDECO is the first and only medicine approved in the EU in this age group to treat the underlying cause of cystic fibrosis for specific mutations in the CFTR gene - Vertex Pharmaceuticals... ► Artikel lesen | |
| CRONOS GROUP | 2,478 | +2,14 % | Cronos Group Inc. to Hold Virtual 2024 Annual Meeting of Shareholders | ||
| VIATRIS | 10,840 | +0,28 % | Viatris Inc - 10-K/A, Annual Report | ||
| INCYTE | 48,100 | -0,39 % | Verhaltene Kauflaune bei Incyte-Aktie (48,5695 €) | CODE Das Papier notiert gegenwärtig bei 51,98 US-Dollar. Der Kurs der Aktie von Incyte zeigt sich derzeit kaum verändert im Vergleich zu der letzten Notierung des vorigen Handelstages. Zur Stunde steht... ► Artikel lesen | |
| BAUSCH HEALTH | 8,149 | +0,05 % | Bausch Health Companies Inc.: Bausch Health to Announce First-Quarter 2024 Results on May 2 | LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a conference... ► Artikel lesen | |
| XTACY THERAPEUTICS | 0,034 | +4,69 % | Xtacy Therapeutics Corp: Xtacy Therapeutics files fiscal 2023 results | ||
| CRESCO LABS | 1,900 | -1,86 % | Cresco Labs cannabis cultivation employees in Massachusetts ditch union | ||
| IONIS PHARMACEUTICALS | 39,500 | +1,65 % | Ionis Pharmaceuticals, Inc.: Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome | - Olezarsen met the primary endpoint with statistically significant reduction of fasting triglycerides and showed substantial, clinically meaningful reduction in acute pancreatitis events -
-... ► Artikel lesen | |
| ALNYLAM PHARMACEUTICALS | 132,80 | -0,86 % | Ahead of Alnylam's key heart disease readout, experts say Pfizer rival would be hard to displace | ||
| ORAMED PHARMACEUTICALS | 2,141 | -7,28 % | Oramed Pharmaceuticals Inc.: Oramed Letter to Shareholders | Initiating Phase 3 oral insulin trial in the United States under a new protocol
JV with Chinese Partner, HTIT
Scilex Senior Secured Note
PeriTech Asset Purchase & Strategic Out-licensing
NEW... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 1,226 | -0,24 % | Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases | Program is the Product of a Research Collaboration between Biolojic Design and Nektar entered in 2021TEL AVIV, Israel and SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- Biolojic Design, a biotechnology... ► Artikel lesen |
Das Unternehmen PROCAPS GROUP SA kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,020 (-0,90 %) liegt der Kurs bei 2,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
